PMP22 and Charcot-Marie-Tooth disease type 1A: However, although inhibiting the expression of a culprit disease gene by siRNA has been successfully demonstrated, the normalization of an overexpressed dosage-sensitive gene, such as PMP22 in CMT1A, has never been considered.